Navigation Links
Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
Date:7/10/2013

ections, and safety. The protocol includes an interim analysis upon the completion of the treatment period in 50% of the patients (60). More information on the clinical trial can be found at clinicaltrials.gov.

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Stockholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can
'/>"/>

SOURCE Ohr Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; ... to progressing its ground-breaking technology platforms to Phase 1 ... the Company delivers the best value for shareholders. ... said the Company currently had an extensive program of ... and academic partnerships and initiatives, and he was working ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
(Date:7/29/2015)... -- Research and Markets ( ... "Global Biosimilars Market, 2015 - 2025" ... Biosimilars Market, 2015 - 2025, report provides an ... With the blockbuster biologics losing patent protection and ... being viewed as viable substitutes to the highly ...
Breaking Biology Technology:Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... Stallergenes,has been granted with the marketing authorisation for ... PEI (Paul Ehrlich,Institute), the biological branch of the ... results of the paediatric pivotal study (VO52),Stallergenes will ... indications., Stallergenes will launch Oralair(R) Grasses in ...
... Clinical Trial Capability into the Frontage ... ... Frontage Laboratories,( http://www.frontagelab.com ) (Malvern and Exton, PA USA ... pre-clinical and,drug development services to the pharmaceutical industry, announced today,it ...
... for Thursday, June 26th at 2:30pm ET, NEW ... ) today announced that Michael S. Weiss, the Company,s,Chairman ... the,Jefferies & Co. Healthcare Conference being held in New ... live on Thursday, June 26th at,2:30pm ET and will ...
Cached Biology Technology:Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany 2Stallergenes : Sublingual Desensitisation Tablets Oralair Grasses Approved in Germany 3Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR) 2Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR) 3Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR) 4Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... microbial communities and the growth of sedimentary rock at ... a surprising discovery about the geological record of life ... sequences of sedimentary rock are dated, and how scientists ... We found microbes change the rate at which calcium ...
... a combination of individual scientific skills, expertise and ... offer the opportunity to build a highly focused ... the urgent need for bringing new antibiotic compounds ... and other antimicrobial agents have saved millions of ...
... Assessment of Climate Change for the Baltic Sea Basin (BACC), ... of past and possible future climate change in the region, ... northern and mid-Europe. One of the key findings is that ... up to five degrees Celsius from now to 2100. More ...
Cached Biology News:Hot springs microbes hold key to dating sedimentary rocks, researchers say 2Unique fungal collection could hold key to future antibiotics 2Unique fungal collection could hold key to future antibiotics 3Climate change in the Baltic Sea basin -- past, present and future 2Climate change in the Baltic Sea basin -- past, present and future 3
... is a modular confocal system that gives ... ultra-compact and lightweight design. The improved scan ... performance to 400nm andits bi-directional scanner provides ... X and Y scan axes rotation and ...
... digital microscope and camera system that does ... adjustment or software installation. Built on Nikon's ... simplicity and advanced technology for users of ... of a macro image and a micro ...
... provides complete components including positive and ... of DNA fragmentation in cultured cells ... BrdU in the procedure provides greater ... Results can be analyzed by fluorescence ...
... LAS-3000 imaging system combines new CCD ... interface, providing significantly improved system sensitivity ... The system is especially dedicated to ... system for Western blotting applications.,Fuiji's LAS-3000 ...
Biology Products: